Standout Papers

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/No... 2003 2026 2010 2018 1.4k
  1. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (2007)
    Jeffrey L. Anderson, Cynthia D. Adams et al. Circulation
  2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023)
    A. Michael Lincoff, Kirstine Brown‐Frandsen et al. New England Journal of Medicine
  3. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. (2007)
    A. Michael Lincoff, Kathy Wolski et al. PubMed
  4. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update) (2012)
    Hani Jneid, Jeffrey L. Anderson et al. Circulation
  5. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention (2003)
    A. Michael Lincoff, John A. Bittl et al. JAMA
  6. Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation (2000)
    Eric Boersma, Karen S. Pieper et al. Circulation
  7. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (2013)
    Jeffrey L. Anderson, Cynthia D. Adams et al. Journal of the American College of Cardiology
  8. Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes (2008)
    Steven E. Nissen, Stephen J. Nicholls et al. JAMA
  9. Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries (1996)
    Willem J. van der Giessen, A. Michael Lincoff et al. Circulation
  10. Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes (2007)
    Steven V. Manoukian, Frederick Feit et al. Journal of the American College of Cardiology
  11. Anthracycline-Induced Cardiotoxicity (1996)
    Kesavan Shan, A. Michael Lincoff et al. Annals of Internal Medicine
  12. Treatment and Prevention of Heparin-Induced Thrombocytopenia (2008)
    Theodore E. Warkentin, Andreas Greinacher et al. CHEST Journal
  13. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update) (2012)
    Hani Jneid, Jeffrey L. Anderson et al. Journal of the American College of Cardiology
  14. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (2011)
    R. Scott Wright, Jeffrey L. Anderson et al. Journal of the American College of Cardiology
  15. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal
  16. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (2024)
    Donna H. Ryan, Ildiko Lingvay et al. Nature Medicine
  17. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials (2024)
    Mikhail Kosiborod, John Deanfield et al. The Lancet
  18. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial (2024)
    Helen M. Colhoun, Ildiko Lingvay et al. Nature Medicine
  19. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial (2024)
    John Deanfield, Subodh Verma et al. The Lancet

Immediate Impact

2 from Science/Nature 119 standout
Sub-graph 1 of 15

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
10 intermediate papers

Works of A. Michael Lincoff being referenced

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
A. Michael Lincoff 20305 13664 5420 409 30.0k
Sabina A. Murphy 29083 17306 5729 482 42.0k
Gilles Montalescot 22451 12008 5700 546 27.9k
Carolyn H. McCabe 29028 16991 5033 181 37.7k
Robert P. Giugliano 17451 13091 4456 544 29.3k
Kenneth W. Mahaffey 31634 12747 10144 646 46.4k
Debabrata Mukherjee 20481 11394 3040 447 28.9k
Dominick J. Angiolillo 20084 11580 5159 589 23.7k
Marc S. Sabatine 27026 22026 3199 499 49.0k
Andrzej Budaj 18444 7648 3352 224 26.0k
Eugene Braunwald 41820 18050 4435 444 56.1k

All Works

Loading papers...

Rankless by CCL
2026